Mebutamate: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:
{{drugbox
<div style="float: right;">
| IUPAC_name        = 2-sec-butyl-2-methylpropane-1,3-diyl dicarbamate
[[File:Mebutamate.png|thumb|none|400px|This image is provided by the National Library of Medicine.]]</div>
| image            =
__NOTOC__
| CAS_number        = 64-55-1
| ATC_prefix        = N05
| ATC_suffix        = BC04
| PubChem          = 6151
| DrugBank          =
| C=10|H=20|N=2|O=4
| molecular_weight  = 232.277 g/mol
| bioavailability  =
| protein_bound    =
| metabolism        =
| elimination_half-life =
| excretion        =
| pregnancy_AU      =  <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US      = <!-- A / B            / C / D / X -->
| pregnancy_category= 
| legal_AU          =  <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA          =  <!--            / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK          =  <!-- GSL        / P      / POM / CD / Class A, B, C -->
| legal_US          =  <!-- OTC                  / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status      =
| routes_of_administration =
}}
'''Mebutamate''' is a [[sedative]] and [[anxiolytic]] drug with anti-[[hypertension|hypertensive]] (blood pressure lowering) effects. It has effects comparable to those of [[barbiturates]] such as [[secobarbital]], but is only around 1/3rd the potency of secobarbital as a sedative. Side effects include [[dizziness]] and [[headaches]].<ref>[http://www.pubmedcentral.nih.gov/pagerender.fcgi?artid=1923261&pageindex=1#page Tetreault L, Richer P, Bordeleau JM. Hypnotic properties of mebutamate: a comparative study of mebutamate, secobarbital and placebo in psychiatric patients. ''Canadian Medical Association Journal''. 1967 Aug 19;97(8):395-8.]</ref>


{{SI}}
{{CMG}}
==Overview==
'''Mebutamate''' ('''Capla''', '''Dormate''') is an [[anxiolytic]] and [[sedative]] [[drug]] with [[antihypertensive]] effects of the carbamate class.<ref name="TaylorFrancis2000">{{cite book | title = Index Nominum 2000: International Drug Directory | url = http://books.google.com/books?id=5GpcTQD_L2oC&pg=PA634 | date = January 2000 | publisher = Taylor & Francis | isbn = 978-3-88763-075-1 | page = 634}}</ref><ref>{{ cite book | title = The Merck Index | edition = 14 | publisher = Merck Publishers | isbn = 978-0-911910-00-1 | at = 5813 }}</ref> It has effects comparable to those of [[barbiturate]]s such as [[secobarbital]], but is only around 1/3 the potency of secobarbital as a sedative. Side effects include [[dizziness]] and [[headaches]].<ref>{{cite pmid | 6037393}}</ref>
Mebutamate is one of many [[Gabaergic|GABAergic]] drugs which act via [[allosteric]] agonism of the [[GABAA receptor|GABA<sub>A</sub> receptor]] at the β-subreceptor similair to barbiturates. In contrast, [[benzodiazepines]] act at the α-subreceptor. As such, carbamates and barbiturates, possess analgesic properties which the benzodiazepine class of drugs do not.
Other carbamates with the same mechanism of action and pharmacological properties include [[meprobamate]], [[carisoprodol]], [[felbamate]], and [[tybamate]]).


== References ==
== References ==
{{reflist|2}}
{{Reflist|2}}


* The Merck Index, 12th Edition. 5813
{{Anxiolytics}}
{{GABAAR PAMs}}


{{pharmacology-stub}}
[[Category:Anxiolytics]]
{{Anxiolytics}}
[[Category:Carbamates]]
{{WikiDoc Sources}}
[[Category:GABAA receptor positive allosteric modulators]]
[[Category:Drug]]

Revision as of 13:49, 7 April 2015

This image is provided by the National Library of Medicine.


WikiDoc Resources for Mebutamate

Articles

Most recent articles on Mebutamate

Most cited articles on Mebutamate

Review articles on Mebutamate

Articles on Mebutamate in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Mebutamate

Images of Mebutamate

Photos of Mebutamate

Podcasts & MP3s on Mebutamate

Videos on Mebutamate

Evidence Based Medicine

Cochrane Collaboration on Mebutamate

Bandolier on Mebutamate

TRIP on Mebutamate

Clinical Trials

Ongoing Trials on Mebutamate at Clinical Trials.gov

Trial results on Mebutamate

Clinical Trials on Mebutamate at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Mebutamate

NICE Guidance on Mebutamate

NHS PRODIGY Guidance

FDA on Mebutamate

CDC on Mebutamate

Books

Books on Mebutamate

News

Mebutamate in the news

Be alerted to news on Mebutamate

News trends on Mebutamate

Commentary

Blogs on Mebutamate

Definitions

Definitions of Mebutamate

Patient Resources / Community

Patient resources on Mebutamate

Discussion groups on Mebutamate

Patient Handouts on Mebutamate

Directions to Hospitals Treating Mebutamate

Risk calculators and risk factors for Mebutamate

Healthcare Provider Resources

Symptoms of Mebutamate

Causes & Risk Factors for Mebutamate

Diagnostic studies for Mebutamate

Treatment of Mebutamate

Continuing Medical Education (CME)

CME Programs on Mebutamate

International

Mebutamate en Espanol

Mebutamate en Francais

Business

Mebutamate in the Marketplace

Patents on Mebutamate

Experimental / Informatics

List of terms related to Mebutamate

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Mebutamate (Capla, Dormate) is an anxiolytic and sedative drug with antihypertensive effects of the carbamate class.[1][2] It has effects comparable to those of barbiturates such as secobarbital, but is only around 1/3 the potency of secobarbital as a sedative. Side effects include dizziness and headaches.[3]


Mebutamate is one of many GABAergic drugs which act via allosteric agonism of the GABAA receptor at the β-subreceptor similair to barbiturates. In contrast, benzodiazepines act at the α-subreceptor. As such, carbamates and barbiturates, possess analgesic properties which the benzodiazepine class of drugs do not.

Other carbamates with the same mechanism of action and pharmacological properties include meprobamate, carisoprodol, felbamate, and tybamate).

References

  1. Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. p. 634. ISBN 978-3-88763-075-1.
  2. The Merck Index (14 ed.). Merck Publishers. 5813. ISBN 978-0-911910-00-1.
  3. PMID 6037393 (PMID 6037393)
    Citation will be completed automatically in a few minutes. Jump the queue or expand by hand

Template:Anxiolytics Template:GABAAR PAMs